Use of rapamycin in a transplant patient who developed cyclosporin neurotoxicity

Pediatric Nephrology

Volumn 16, Issue 10, 2001, Pages 777-778

  Hodges, C B ^a   Maxwell, H ^a   Beattie, T J ^a   Murphy, A V ^a   Jindal, R M ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Cyclosporin neurotoxicity; P450 enzyme drug interactions; Paediatric renal transplant; Rapamycin

Indexed keywords

ANTICONVULSIVE AGENT; CREATININE; CYCLOSPORIN; CYTOCHROME P450; ENZYME INDUCING AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENYTOIN; PREDNISOLONE; RAPAMYCIN;

ARTICLE; CASE REPORT; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG USE; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; NEUROTOXICITY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SCHOOL CHILD;

ANTICONVULSANTS; CHILD; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; PHENYTOIN; SEIZURES; SIROLIMUS;

EID: 0034833666     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004670100662     Document Type: Article

References (6)

1. Complex partial status epilepticus associated with cyclosporin A therapy
2. Advancing the art of immunosuppression with the science of pharmacology
3. Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
4. Sirolimus (rapamycin)-based therapy in human renal transplantation
5. Rapamycin: Distribution, pharmacokinetics and therapeutic range investigations: An update
6. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin